

Medtronic introduces IN.PACT Admiral DCB in Japan

17 August 2018 | News

IN.PACT Admiral DCB is a clinically proven, primary endovascular therapy that treats femoropopliteal disease, reduces interventions, and preserves future treatment options.



Dublin-based Medtronic has announced the commercial launch of the IN.PACT Admiral Drug-Coated Balloon (DCB) in Japan.

IN.PACT Admiral DCB is a clinically proven, primary endovascular therapy that treats femoropopliteal disease, reduces interventions, and preserves future treatment options.

Last year, the Japanese Ministry of Health, Labor and Welfare (MHLW) granted approval for IN.PACT Admiral for the treatment of peripheral artery disease (PAD) in the upper leg specifically, in the thigh (superficial femoral arteries (SFA) and behind the knee (popliteal arteries).

This development follows the completion of a post-market clinical trial, which was conducted on 300 subjects.